<DOC>
	<DOC>NCT00464256</DOC>
	<brief_summary>The primary objective is to assess the efficacy a 20mg/day fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period.</brief_summary>
	<brief_title>Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Smokers smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit Motivated to quit with a score greater than or equal to 6 on the tenpoint Motivation Scale Non tobacco cigarettes consumption Chronic use of marijuana Pregnancy, breastfeeding Any clinically significant disease that might interfere with the efficacy or safety evaluation of the study drug Concomitant use of drugs as an aid to smoking cessation or that might induce weight change</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>abstinence</keyword>
</DOC>